| Literature DB >> 26784936 |
Chi B Vu1, Jean E Bemis1, Ericka Benson1, Pradeep Bista1, David Carney1, Richard Fahrner1, Diana Lee1, Feng Liu1, Pallavi Lonkar1, Jill C Milne1, Andrew J Nichols1, Dominic Picarella1, Adam Shoelson1, Jesse Smith1, Amal Ting1, Allison Wensley1, Maisy Yeager1, Michael Zimmer1, Michael R Jirousek1.
Abstract
This report describes the synthesis and preliminary biological characterization of novel fatty acid niacin conjugates and fatty acid salicylate conjugates. These molecular entities were created by covalently linking two bioactive molecules, either niacin or salicylic acid, to an omega-3 fatty acid. This methodology allows the simultaneous intracellular delivery of two bioactives in order to elicit a pharmacological response that could not be replicated by administering the bioactives individually or in combination. The fatty acid niacin conjugate 5 has been shown to be an inhibitor of the sterol regulatory element binding protein (SREBP), a key regulator of cholesterol metabolism proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase, and NPC1L1. On the other hand, the fatty acid salicylate conjugate 11 has been shown to have a unique anti-inflammatory profile based on its ability to modulate the NF-κB pathway through the intracellular release of the two bioactives.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26784936 DOI: 10.1021/acs.jmedchem.5b01961
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446